APA Alıntı

Cummings, J., Ranson, M., LaCasse, E., Ganganagari, J. R., St-Jean, M., Jayson, G., . . . Dive, C. (2006). Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Nature Publishing Group.

Chicago Stili Alıntı

Cummings, J., M. Ranson, E. LaCasse, J R. Ganganagari, M. St-Jean, G. Jayson, J. Durkin, ve C. Dive. Method Validation and Preliminary Qualification of Pharmacodynamic Biomarkers Employed to Evaluate the Clinical Efficacy of an Antisense Compound (AEG35156) Targeted to the X-linked Inhibitor of Apoptosis Protein XIAP. Nature Publishing Group, 2006.

MLA Alıntı

Cummings, J., et al. Method Validation and Preliminary Qualification of Pharmacodynamic Biomarkers Employed to Evaluate the Clinical Efficacy of an Antisense Compound (AEG35156) Targeted to the X-linked Inhibitor of Apoptosis Protein XIAP. Nature Publishing Group, 2006.

Uyarı: Bu alıntı herzaman %100 doğru olmayabilir..